Fulcrum Therapeutics, Inc. Banner Image

Fulcrum Therapeutics, Inc.

  • Ticker FULC
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Fulcrum Therapeutics, Inc. Logo Image
  • 51-200 Employees
  • Based in Cambridge, Massachusetts
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinicalMore development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and is advancing losmapimod to Phase 3 for the treatment of COVID-19. Fulcrum also anticipates filing an IND in the third quarter with initiation of a clinical trial in the fourth quarter of 2020 with FTX-6058 for the treatment of sickle cell disease.
4.8 / 5.0 (137)

Fulcrum Therapeutics, Inc. reports have an aggregate usefulness score of 4.8 based on 137 reviews.

Fulcrum Therapeutics, Inc.

Most Recent Annual Report

Fulcrum Therapeutics, Inc.
MOST RECENT 2023 Annual Report and Form 10K

Older/Archived Annual Reports

Fulcrum Therapeutics, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!